Searched for
LUPIN EBITDA
Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...- Suryoday Small Finance Bank reports Q4 profit at Rs 49 croreSuryoday Small Finance Bank reported a strong turnaround in fourth-quarter earnings with improved profitability and higher operating profit...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Lupin shares gain 3%, up for second straight session. Here’s whyLupin shares saw an uptick after Jefferies raised its target price and reiterated a “Buy” rating post-strong Q2 results. The US business hi...
- Lupin shares jump 2% as Q2 PAT soars 73% YoY to Rs 1,485 croreLupin shares rose on Friday after the pharma major reported a robust 73% YoY surge in Q2 FY26 PAT to Rs 1,485 crore, driven by strong sales...
- Lupin shares surge 6%, hit 52-week high post robust Q1 resultLupin Share Price: Lupin's shares jumped 6% to a 52-week high after the company announced a 77.2% increase in net profit for the June quart...
- Why CLSA is bearish on Lupin & bullish on LIC Housing FinanceLIC Housing's spread will improve in FY23 but may contract in FY24, said CLSA. "Home loan yields have risen 80-90 basis points for the indu...
- Market Movers: Lupin shares in delicate condition on margin squeezeLupin's EBITDA margins contracted by 580 bps quarter-on-quarter (QoQ) and 1,050 bps YoY at 9.9 per cent even as profit rose 24 per cent YoY
- How did India's Big Pharma fare in the December Quarter?Sun Pharma reported its highest-ever quarterly sales, and Cipla posted the highest-ever Ebitda margin in the company's recent history. Lupi...
- US show a plus for Cipla, Lupin confident of recoveryThe domestic business grew 6 per cent, showing the impact of a high base effect.
- Key takeaways from Lupin’s Q3 earningsUS sales jumped 13.50 per cent QoQ to Rs 1417.40 crore in Q3FY19.
- Lupin Q3 results today: Here's what experts sayAccording to an ET Now poll, the drug maker is likely to report a 7 per cent YoY jump in net sales.
- Buy Lupin, target Rs 1190: HDFC SecuritiesBuy Lupin Ltd. at a price target of Rs 1190.
- Add Lupin Ltd. target Rs 815: ICICI DirectAdd Lupin Ltd. at a price target of Rs 815.
- Lupin makes impairment provision for GavisLupin took a hit worth Rs 1,464.35 crore on US-based Gavis, which it acquired in 2015 for $880 million (Rs 5,610 crore then).
- Lupin posts 59% drop in consolidated net profit at Rs 358 crore in Q1The pharma firm had reported Rs 881.95 crore profit in the corresponding quarter last year.
- Buy Lupin, target Rs 2040 : HDFC SecuritiesThe brokerage said investors should monitor guidance on R&D expense for FY17, updates on launches, Goa facility remediation and progress of...
- Lupin disappoints with Q1 nos; acquisition looks expensive; stock may correct: Mayuresh JoshiQ1 numbers were disappointing; acquisition looks expensive and, at the current level, Lupin stock also looks quite expensive to us, says Jo...
- Lupin likely to sign $1.5 billion deal with Merck SeronoLupin will manufacture Merck Serono’s $1.5 billion worth branded mature drugs at its facilities. The company will also get marketing rights...
- Lupin rallies 4.5% in a weak market post Q3 results; top Nifty gainerLupin rallied as much as 4.8% in trade on Monday in a weak market, after the drugmaker reported a 42% growth in its quarterly net profit.
Load More
